CNTX News and Press, Context Therapeutics Inc. From 05/02/24

2024-05-02 10:00:43 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...

A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...

2024-05-02 08:00:04 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics Read the full article on Seeking Alpha For...

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (N...

Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “C...

2024-04-01 09:11:44 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics Read the full article on Seeking Alpha For...

PHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced that on March 28, 2024, the Company submitted an Investigational Ne...

2024-03-21 10:44:50 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics Read the full article on Seeking Alpha For...

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therape...

2023-11-09 17:45:48 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics For further details see: Context Therapeutics ...